Kornimate/medical-research-clean huggingface dataset:
pretreatment botulinum toxin in head and neck cancer surgery

Conditions: Head Neck Cancer; Xerostomia Following Radiotherapy

Summary: head and neck cancer care, including tumors of the mouth, nose, throat and voice box, often requires radiation for cure to be achieved. despite advances in radiation, 40% to 60% of patients experience a significant dry mouth (xerostomia) following radiotherapy. several factors are associated with severe xerostomia including older age, advanced stage disease and tumor location. currently, no pragmatic treatment strategy exists to reduce the risk of radiation-related xerostomia in patients with head and neck cancer. the investigators propose the use of a botulinum neurotoxin injected into the at-risk salivary glands before radiation as a strategy to preserve salivary gland function during radiation treatments and reduce xerostomia.


Eligibility criteria:
inclusion criteria: * newly diagnosis ajcc 8th edition stage iii/iva mucosal head and neck squamous cell carcinoma requiring definitive radiotherapy (with or without chemotherapy). exclusion criteria: * previous radiation to the head and neck * previous treatment for head and neck cancer * personal history of xerostomia * hypersensitivity to onabotulinumtoxina * previous major salivary gland surgery * previous exposure to radioactive iodine therapy

Keywords: head and neck cancer radiation induce xerostoma botulinum toxin salivary glands
activity based program to improve quality of life outcomes in women diagnosed with cancer

Conditions: Cancer

Summary: implementation and evaluation of an activity based program to improve quality of life outcomes in women diagnosed with cancer. demonstrate improved life satisfaction (with evidenced gathered at three consecutive periods and geographical locations through quality of life surveys).

this research study focused on developing and implementing eight one-week activity camps in the summer of 2012, 2013, and 2014 for women diagnosed with cancer. each camp was held in a different geographical location: rural (renovo, pa), suburban (gilda's club in warminster, pa), md anderson of camden, and urban (university of the sciences with the cancer support community of philadelphia). the focus of this programming was to allow women to engage in activities they may not be engaged in since the diagnosis of cancer and to provide them with opportunities to socially interact and communicate with individuals who may have encountered the same difficulties as them. quality of life information was collected before, during and after implementation of the activity program. the main objective was to demonstrate improved life satisfaction (with evidenced gathered at three consecutive periods and geographical locations through quality of life surveys). 77 women were recruited over a three year period. 6 dropped out and 71 completed the entire study.

Eligibility criteria:
inclusion criteria: * women diagnosed with cancer * age of 21 or older * a clearance from their md to participate in the activity program. exclusion criteria: not applicable (na) * none

Keywords: quality of life occupation
vigorous exercise for depressed smokers

Conditions: Nicotine Dependence; Depression

Summary: in this project the investigators will develop and pilot test a supervised, vigorous intensity exercise intervention for depressed female smokers. if the pilot intervention is successful the investigators will have a blueprint for a large randomized controlled trial. the long term objective is to develop interventions for depressed women that will ultimately reduce their risk of tobacco-caused disease and mortality.

this project will be the first to evaluate supervised vigorous exercise for depressed smokers

Eligibility criteria:
inclusion criteria: 1. depressed (ces-d) score 16 or above 2. 18 years of age 3. female gender 4. sedentary 5. current cigarette smoker exclusion criteria: 1. smoking cessation medication 2. not able to exercise medically

Keywords: exercise depression smoking
a retrospective study of newly-diagnosed pcnsl treated with a methotrexate (mtx) and orelabrutinib-based regimen

Conditions: Primary Central Nervous System Lymphoma

Summary: this study was a single-centre, retrospective study that retrospectively collected first-line pcnsl patients receiving methotrexate-based chemotherapy ± orelabrutinib at huashan hospital of fudan university. the study was divided into two retrospective cohorts, cohort a was a cohort of patients receiving methotrexate-based chemotherapy alone, and cohort b was a cohort of patients receiving methotrexate-based chemotherapy + orelabrutinib.

the study was divided into two retrospective cohorts of approximately 35-40 patients each. cohort a was the cohort of patients who received methotrexate-based chemotherapy alone, and cohort b was the cohort of patients who received methotrexate-based chemotherapy + orelabrutinib. statistical analyses such as propensity score analysis (psm) and inverse probability weighted (iptw) analysis were performed, focusing on comparing and analysing the short-term efficacy data (orr, cr) and long-term efficacy data (pfs, os) of the two cohorts.

Eligibility criteria:
inclusion criteria: * pathologically confirmed primary central nervous system lymphoma * methotrexate-based chemotherapy ± orelabrutinib regimen as first-line treatment for patients exclusion criteria: * patients receiving ≤2 cycles of treatment without efficacy evaluation * those with uncontrolled or significant cardiovascular disease, including: uncontrolled diabetes mellitus, severe cardiac, pulmonary, hepatic, renal insufficiency) and haematological, endocrine system lesions, history of other uncontrollable malignancies
phase 3 study of kp-100it in subjects with acute spinal cord injury

Conditions: Acute Spinal Cord Injury

Summary: this study is non-randomized, multicenter, confirmatory study by intrathecal administration of kp-100it, code of hgf (hepatocyte growth factor ) formulation for intrathecal injection, in subjects with acute spinal cord injury.


Eligibility criteria:
inclusion criteria: * at the time of consent (whether oral or written consent), the patient's age is over 18 years old and under 89 years old * patients who have suffered a cervical spinal cord injury within the past 78 hours whose ais classification was a at 66 - 78 hours after injury-written informed consent has been obtained exclusion criteria: * the injury site is c1-c2 or c2-c3 * the patient cannot start rehabilitation necessary for recovery of function at an early stage, for example because tracheal intubation, tracheotomy, or mechanical ventilatory support is necessary * it is predicted that it will not be possible to administer the first dose of the study drug within 78 hours after the cervical spinal cord injury * a history of sci (spinal cord injury), or abnormal findings in the spinal cavity or marked breakdown of the meninges other than sci * efficacy and safety cannot be evaluated properly due to such as concurrent multiple external trauma or concurrent organ injury * high dose steroid therapy administered for spinal cord injury * disease such as serious liver disorder, renal disease, heart disease, blood dyscrasia, metabolic disease, or infections requiring systemic therapy * history of malignant tumor * participation in a clinical study or research of pharmaceuticals or medical devices within 1 month before registration * drug allergies to drugs that will be (or may be) used * administration of the study drug to the site of spinal cord injury is inappropriate for a reason such as intrathecal infection or intrathecal mass * problems with the subject's ability to give informed consent in person * the subject is breastfeeding or possibly pregnant * the subject cannot be expected to survive more than 180 days after the start of administration of the study drug, in the judgement of the investigator * it is inappropriate for the subject to be included in the study, in the judgement of the investigator

Keywords: hepatocyte growth factor hgf kp-100it kp-100 intrathecal injection
pet/ct evaluation of treatment response in breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to develop positron emission tomography (pet) - computed tomography (ct) pet/ct imaging methods for looking at the effects of chemotherapy in breast cancer.


Eligibility criteria:
inclusion criteria * subjects must have histologically proven breast cancer * subjects are being considered for preoperative chemotherapy * subjects must be ≥ 18 years old. sensor sub-study only * palpable subcutaneous or known disease with one surface \<1cm below surface of skin. * a subset of patients who have a mass located on any surface of the breast that is accessible for lucerno sensor placement will have additional testing. exclusion criteria * children will be excluded from this study. * pregnant women and women who are breast feeding will be excluded from this study. (the vanderbilt university medical center radiology "pet procedure screening form" will be used to identify and exclude subjects who are pregnant or breastfeeding. a urine pregnancy test/or serum beta hcg will also be performed for women of child bearing potential). * patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study. * intraluminal lesions will be excluded from the sensor sub-study. * non biopsy proven malignancy will be excluded from this study. * palpable subcutaneous or known disease with one surface \>1cm below surface of skin will be excluded from the sensor sub-study. * draining or exposed malignant tumor will be excluded from the sensor sub-study.
asthma partnership for minority children

Conditions: Asthma; Lung Diseases

Summary: to evaluate the efficacy of a community-based intervention to improve asthma management for parents, children and health care providers.

design narrative: forty-two (42) elementary schools in urban baltimore and washington, dc, served as recruitment sites and approximately 300 students with moderate to severe asthma were enrolled. all participants enrolled in the a+ asthma program. primary care practitioners of these students were randomized to a minimal contact program or to the a+ asthma physician partnership. they were offered a menu of educational offerings to improve their knowledge and skills. the primary outcome measure was emergency care use. secondary measures included physician practices, hospitalization, health care utilization, restricted activities, medication use, school absences and coping skills. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
ctrp3 and progranulin in patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: visceral obesity is the one of the major causes of cardiovascular morbidity and mortality in industrialized countries. adipose tissue secretes various kinds of bioactive molecules termed adipokines which contribute to the development of obesity-related disorders including cardiovascular disease (cvd). progranulin and ctrp3 are recently discovered novel adipokines. therefore, the investigators tried to compare circulating ctrp-3 and progranulin levels in patients with cad and investigated whether ctrp-3 or progranulin is significantly associated with cad prevalence after adjustment for well-known cad risk factors.

ctrp-3 (synonyms cors-26, cartducin and cartonectin) is a potent anti-inflammatory adipokine that inhibits proinflammatory pathways in monocytes and adipocytes. using a recently developed enzymelinked immunosorbent assay (elisa), we reported that circulating ctrp-3 levels were elevated in patients with glucose metabolism dysregulation. progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 (il-6) in adipose tissue. we previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue. moreover, the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque, which may contribute to the progression of atherosclerosis there has been no previous report on the implication of ctrp-3 or progranulin in humans with cardiovascular disease (cad). in the present study, we compared circulating ctrp-3 and progranulin levels in patients with cad and investigated whether ctrp-3 or progranulin is significantly associated with cad prevalence after adjustment for well known cad risk factors.

Eligibility criteria:
inclusion criteria: * acute myocardial infarction * unstable angina * stable angina pectoris exclusion criteria: for control group, we exclude the participants who had * a history of cvd (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization) * type 2 diabetes * stage 2 hypertension (resting blood pressure, ≥160/100 mmhg) * malignancy * severe renal or hepatic disease

Keywords: ctrp-3 progranulin coronary artery disease
pelvic and hip morphometry in piriformis syndrome

Conditions: Piriformis Muscle Syndrome; Anthropometry

Summary: in this case-control study, 23 patients diagnosed as ps by diagnostic injection with ultrasound guidance were selected as the study group. 22 patients who were excluded from the diagnosis of ps and had anteroposterior (ap) direct radiographic imaging were evaluated as the control group. on the ap pelvic graph, the femoral neck-shaft angle, the distances between predetermined bony landmarks were measured blindly without knowing the diagnosis, and the findings were compared statistically. this study aims to evaluate whether the anatomical structure of the pelvis predisposes to the etiopathogenesis of the piriformis syndrome.

piriformis syndrome (ps) is a neuromuscular disorder consisting of pain and symptoms caused by compression of the sciatic nerve and other structures that pass under the piriformis muscle (pm). due to difficulties in diagnosis, ps is confused with other pathologies such as lumbar disc pathology, lumbosacral radiculopathy, and sacroiliac dysfunction. as a result, patients are exposed to unnecessary and ineffective treatments, even surgery. the main problems in the ps diagnosis are the absence of objective physical examination findings, radiological findings, and a clear etiology. when the pathophysiology and etiology of ps are considered, there is no identifiable cause in most patients. previous studies suggest that trauma, anatomical variations, and the trigger point in the muscle may cause ps. no study in the literature radiologically examined the pelvis or hip bone morphological features in ps to the best of our knowledge. this study aims to determine whether pelvic or hip bone morphology features pose a risk for ps in this study.

Eligibility criteria:
for piriformis syndrome group (study group); inclusion criteria: * a dramatic relief of pain following piriformis muscle local anesthetic injection exclusion criteria: * having a neurological deficiency * having lumbar, sacroiliac, hip, and thoracolumbar pathology (inflammatory or degenerative) * operation history at the lumbar and hip region * being in the gestational or lactational period * body mass index of greater than 35 * history of inflammatory or infectious disease * active psychiatric illness, severe systemic, vascular or malign disease for the control group inclusion criteria: -having anteroposterior pelvic radiographs for other medical reasons exclusion criteria: * having a present piriformis syndrome or a history of piriformis syndrome * having a neurological deficiency * having lumbar, sacroiliac, hip, and thoracolumbar pathology (inflammatory or degenerative) * operation history at the lumbar and hip region * being in the gestational or lactational period * body mass index of greater than 35 * history of inflammatory or infectious disease * active psychiatric illness, severe systemic, vascular or malign disease

Keywords: anthropometry pelvic bones muscle syndrome, piriformis prospective studies case-control studies femur neck / pathology
effect of lamotrigine on cognition in nf1

Conditions: Neurofibromatosis Type 1

Summary: the purpose of this study is to determine whether lamotrigine can improve cognitive and neurophysiological deficits in adolescents with neurofibromatosis type 1.

cognitive deficits in the autosomal dominant disorder neurofibromatosis type 1 (nf1) typically consist of a lower than average iq, impaired visual-spatial learning, attention problems and impaired executive functioning. these deficits have a substantial influence on the daily life of pediatric and adolescent individuals with nf1. one of the key underlying mechanisms of these deficits is an increased gamma-aminobutyric acid (gaba)-ergic inhibition and a subsequent decrease in synaptic plasticity. the encore laboratory has recently shown that loss of the nf1-gene is associated with attenuated function of the hyperpolarization-activated cyclic nucleotide-gated channel 1 (hcn1). these channels, enriched in membranes of inhibitory interneurons, play an important role in the pathophysiology underlying the cognitive deficits in nf1. lamotrigine, an hcn-agonist, restored function of hcn1, together with the electrophysiological and visual-spatial learning deficits in nf1-mice. thus, lamotrigine is a novel candidate drug for treating cognitive deficits associated with nf1.

Eligibility criteria:
inclusion criteria: * nf1 patients with a genetically confirmed diagnosis * age 12-17.5 years at inclusion * oral and written informed consent by parents and assent from participants exclusion criteria: * segmental nf1 * severe hearing problems or deafness * severe visual problems or blindness * use of the following medication, as of interaction with lamotrigine: phenytoin, carbamazepine, phenobarbital, primidon, rifampicin, atazanavir/ritonavir, lopinavir/ritonavir, oxcarbazepine, topiramate, oral contraceptive pill including stop-week (estrogen and progesterone) and valproic acid during 3 months before inclusion. * use of psycho-active medication other than methylphenidate * previous allergic reactions to anti-epileptic drugs * epilepsy or epilepsy in the past * suicidal thoughts or behaviour * renal insufficiency * liver insufficiency * pregnancy * brain tumour or other brain pathology potentially influencing the outcome measures

Keywords: neurofibromatosis type 1 nf1 cognition learning problems lamotrigine transcranial magnetic stimulation tms
a study of effect of megakaryocytes and platelets in breast cancer

Conditions: Breast Cancer

Summary: determining if megakaryocytes and platelets are harmful or helpful in breast cancer cell metastasis

the purpose of this study is to determine how megakaryocytes (cells in the bone marrow responsible for making platelets, which are necessary for blood clotting) affect the survival and growth/division patterns of breast cancer stem cells, and the effects of breast cancer cells on megakaryocyte survival and function. through chart review, the study team will look at the relationship between different blood components and different breast cancer diagnoses.

Eligibility criteria:
inclusion criteria: cohort 1-biopsy negative * females age 18 and above cohort 2-biopsy positive for carcinoma in situ (ductal, lobular, or other) * females age 18 and above * any subtype of breast cancer cohort 3-biopsy positive for stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other) * females age 18 and above * any subtype of breast cancer * have no distant metastases cohort 4-stage 4 metastatic disease * females age 18 and above * any subtype of breast cancer exclusion criteria: * previous diagnosis with a known platelet disorder such as: bernard soulier disease, jacobsen syndrome, lowe syndrome, thrombocytopenia, thrombotic thrombocytopenic pupura, von willebrand disease, or the equivalent. any condition in which antiplatelet or anticoagulant therapy with one of the following medications is being prescribed: clopidogrel (plavix), warfarin (coumadin or jantoven), prasugrel (effient), or ticagrelor (brilinta). cohort 1-biopsy negative * males * females less than age 18 cohort 2-biopsy positive for carcinoma in situ (ductal, lobular, or other) * males * females less than age 18 * currently undergoing neoadjuvant therapy cohort 3-biopsy positive for stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other) * males * females less than age 18 * presence of distant metastases * currently undergoing neoadjuvant therapy cohort 4-stage 4 metastatic disease * males * females less than age 18 * currently undergoing neoadjuvant therapy * less than 30 days from last adjuvant treatment for stage i-iii breast cancer (may be on trastuzumab, pertuzumab, or endocrine therapy only for maintenance therapy from their prior breast cancer diagnosis)

Keywords: megakaryocytes platelets
the efficacy of group therapy in ultra-orthodox jewish young men diagnosed with type one diabetes

Conditions: Behavioral Changes

Summary: the purpose of this study is to compare the influence of an intervention program especially designed to young ultra orthodox men that were diagnosed with diabetes type one.


Eligibility criteria:
inclusion criteria: * young ultra-orthodox men diagnosed with diabetes type one. exclusion criteria: * psychiatric illness .
a prospective, unmasked evaluation of the istent in patients with primary open-angle glaucoma

Conditions: Glaucoma; Eye Diseases; Glaucoma, Open-Angle

Summary: prospective, unmasked, evaluation of the istent in patients that have primary open-angle glaucoma (oag). stent implantation in one eye will be used for analysis, with medication added at 6 months, as required.

one hundred patients will be enrolled in the study at up to 21 sites; follow-up is through 1 year.

Eligibility criteria:
inclusion criteria: * diagnosis of primary open-angle glaucoma * male or female at least 18 years of age and able to provide written informed consent * mean iop (at baseline visit after washout of any medications) must be at least 22 mm hg and no greater than 38 mm hg * likely to be available and willing to attend follow-up visits exclusion criteria: * angle closure glaucoma * secondary glaucomas * prior glaucoma procedures * elevated episcleral venous pressure from history of active thyroid orbitopathy, carotid-cavernous fistula, orbital tumors, or orbital congestive disease

Keywords: primary open angle glaucoma (poag) oag glaucoma